Immuno-oncology treatment developer Corvus has boosted its total funding to more than $100m after securing funding from backers including Novo and Roche.

Corvus Pharmaceuticals, a US-based immuno-oncology therapy developer, has closed a $75m series B round featuring Roche Venture Fund and Novo Ventures, subsidiaries of pharmaceutical firms Roche and Novo.

The round was led by Rock Springs Capital Management and included Fidelity Management and Research Company, Blackrock, T. Rowe Price, Jennison Associates, Cormorant Asset Management, Sphera Funds Management, VenBio Select, Cowen Private Investments, Orbimed and Adams Street Partners.

Cowen & Company advised Corvus for the transaction, which was backed by 33 investors,…